📊 CNTX Key Takeaways
Is Context Therapeutics Inc. (CNTX) a Good Investment?
Context Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and negative profitability metrics that render traditional financial analysis unreliable. While the company maintains strong liquidity with $76.9M in cash, its burn rate of $17.4M annually in operating losses creates a runway of approximately 4-5 years assuming no further fundraising, making near-term viability dependent entirely on clinical trial success and upcoming capital raises.
Context Therapeutics shows strong balance-sheet liquidity with $76.94M of cash, no long-term debt, and very low liabilities relative to equity, which supports near-term operating flexibility. However, the core fundamentals remain weak: revenue is still very small at $2.24M, operating and net losses are extremely large relative to sales, and free cash flow is deeply negative, indicating the business is not yet demonstrating scalable or durable profitability. The revenue growth is notable, but the quality of that growth appears low until it translates into materially improved margins and reduced cash burn.
Why Buy Context Therapeutics Inc. Stock? CNTX Key Strengths
- Substantial cash position of $76.9M provides near-term operational runway
- Strong balance sheet with minimal debt (Debt/Equity of 0.00x) and $73.2M stockholders equity
- Excellent current and quick ratios (13.10x) indicating minimal near-term liquidity constraints
- Revenue growth of 112.7% YoY suggests emerging commercial traction or milestone achievements
- Very strong liquidity profile with $76.94M cash and 13.10x current and quick ratios
- Debt-free capital structure reduces financial risk and interest burden
- Revenue grew 112.7% year over year, indicating some top-line momentum
CNTX Stock Risks: Context Therapeutics Inc. Investment Risks
- Massive operating losses (-$25.9M) and net losses (-$23.1M) with no clear path to profitability
- Negative free cash flow of -$17.5M annually with operating cash burn consuming capital reserves
- Pre-clinical/early-stage pharmaceutical company dependent on uncertain drug development outcomes
- Extremely negative profitability margins (Operating Margin -1158.1%, Net Margin -1032.9%) indicate fundamental unprofitability
- Current revenue of $2.2M is immaterial relative to operating expenses, suggesting minimal commercial validation
- Operating margin of -1158.1% and net margin of -1032.9% show the business is far from economic sustainability
- Negative operating cash flow and free cash flow of about $17.5M indicate ongoing cash burn
- Revenue base remains too small relative to cost structure, raising questions about growth quality and scalability
Key Metrics to Watch
- Operating cash burn rate and cash runway duration
- Clinical trial progress and regulatory milestone achievements
- Revenue growth trajectory and commercialization progress
- Need for and terms of future capital raises
- Quarterly operating cash burn relative to cash balance
- Revenue growth alongside improvement in operating loss and net margin
Context Therapeutics Inc. (CNTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.10x current ratio provides a solid financial cushion.
CNTX Profit Margin, ROE & Profitability Analysis
CNTX vs Healthcare Sector: How Context Therapeutics Inc. Compares
How Context Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Context Therapeutics Inc. Stock Overvalued? CNTX Valuation Analysis 2026
Based on fundamental analysis, Context Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Context Therapeutics Inc. Balance Sheet: CNTX Debt, Cash & Liquidity
CNTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Context Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.46 indicates the company is currently unprofitable.
CNTX Revenue Growth, EPS Growth & YoY Performance
Context Therapeutics Inc. Dividends, Buybacks & Capital Allocation
CNTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Context Therapeutics Inc. (CIK: 0001842952)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNTX
What is the AI rating for CNTX?
Context Therapeutics Inc. (CNTX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNTX's key strengths?
Claude: Substantial cash position of $76.9M provides near-term operational runway. Strong balance sheet with minimal debt (Debt/Equity of 0.00x) and $73.2M stockholders equity. ChatGPT: Very strong liquidity profile with $76.94M cash and 13.10x current and quick ratios. Debt-free capital structure reduces financial risk and interest burden.
What are the risks of investing in CNTX?
Claude: Massive operating losses (-$25.9M) and net losses (-$23.1M) with no clear path to profitability. Negative free cash flow of -$17.5M annually with operating cash burn consuming capital reserves. ChatGPT: Operating margin of -1158.1% and net margin of -1032.9% show the business is far from economic sustainability. Negative operating cash flow and free cash flow of about $17.5M indicate ongoing cash burn.
What is CNTX's revenue and growth?
Context Therapeutics Inc. reported revenue of $2.2M.
Does CNTX pay dividends?
Context Therapeutics Inc. does not currently pay dividends.
Where can I find CNTX SEC filings?
Official SEC filings for Context Therapeutics Inc. (CIK: 0001842952) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNTX's EPS?
Context Therapeutics Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CNTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Context Therapeutics Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CNTX stock overvalued or undervalued?
Valuation metrics for CNTX: ROE of -31.6% (sector avg: 15%), net margin of -1,032.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CNTX stock in 2026?
Our dual AI analysis gives Context Therapeutics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CNTX's free cash flow?
Context Therapeutics Inc.'s operating cash flow is $-17.4M, with capital expenditures of $33.9K. FCF margin is -781.5%.
How does CNTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,032.9% (avg: 12%), ROE -31.6% (avg: 15%), current ratio 13.10 (avg: 2).